Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open-angle glaucoma: A pilot study

Clinical and Experimental Ophthalmology

Volumn 41, Issue 2, 2013, Pages 155-158

  Desai, Rajen U ^a   Singh, Kuldev ^b   Lin, Shan C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ahmed valve; Glaucoma; Ranibizumab; VEGF; Wound healing

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PILOT STUDY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CATARACT EXTRACTION; FEMALE; GLAUCOMA DRAINAGE IMPLANTS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; PILOT PROJECTS; POSTOPERATIVE CARE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875522020     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2012.02836.x     Document Type: Article

References (20)

1. Colwell AS, Beanes SR, Soo C etal. Increased angiogenesis and expression of vascular endothelial growth factor during scarless repair. Plast Reconstr Surg 2005; 115: 204-12.
2. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008; 88: 579-90.
3. Li Z, Van Bergen T, Van de Veire S etal. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009; 50: 5217-25.
4. Jue A. Angiogenesis: trabeculectomy and bevacizumab. Semin Ophthalmol 2009; 24: 122-5.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010; 21: 112-17.
6. Mathew R, Barton K. Anti-vascular endothelial growth factor therapy in glaucoma filtration surgery. Am J Ophthalmol 2011; 152: 10-15.
7. Memarzadeh F, Varma R, Lin L etal. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009; 50: 3233-7.
8. How A, Chua JL, Charlton A etal. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2010; 51: 928-32.
9. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006; 37: 148-50.
10. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008; 115: 2141-5.
11. Sengupta S, Venkatesh R, Ravindran RD. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma 2011; [Epub ahead of print] doi:10.1097/IJG.0b013e31821826b2 (accessed 3 May 2011).
12. Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol 2010; 150: 399-403. e1.
13. Bochmann F, Kaufmann C, Becht CN etal. SRCTN12125882 - influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - study protocol. BMC Ophthalmol 2011; 11: 1-9.
14. Rojo-Arnao M, Albis-Donado OD, Lliteras-Cardin M, Kahook MY, Gil-Carrasco F. Adjunctive bevacizumab in patients undergoing Ahmed valve implantation: a pilot study. Ophthalmic Surg Lasers Imaging 2011; 42: 132-7.
15. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994; 58: 439-51.
16. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-82.
17. Nomoto H, Shiraga F, Kuno N etal. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 4807-13.
18. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-72.
19. Krohne TU, Eter N, Holz FG etal. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146: 508-12.
20. Bakri SJ, Snyder MR, Reid JM etal. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9.